[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-discomfort\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-discomfort":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100602141","nt-ii-collagen-for-joint-discomfort-and-function-100602141",false,"NCT07119645","NT-II™ Collagen for Joint Discomfort and Function","A Decentralized, Randomized, Active-Controlled Clinical Trial Investigating the Effects of NT-II™ (Salmon Undenatured Type II Collagen) on Activity-Related Knee Discomfort and Functional Performance in Healthy Adults","NTII-JOINT","Inclusion Criteria:\n\n* Adults aged 20 to 65 years.\n* Self-reported, reproducible knee discomfort associated with any knee-loading activities for at least 3 months prior to screening.\n* Discomfort must occur in at least one knee during a nominated aggravating activity at least twice per week and subside with rest.\n* VAS rating of 30 mm to 75 mm during the past week for the nominated activity.\n* No current diagnosis of structural joint disease (e.g., osteoarthritis).\n* Engages in physical activity involving knee-loading movements at least twice weekly for 20+ minutes.\n* BMI between 20.0 and 32.5 kg\u002Fm².\n* In good general health with no significant medical comorbidities.\n* Able and willing to provide informed consent.\n* Capable of completing study procedures remotely using mobile technology.\n\nExclusion Criteria:\n\n* Persistent knee pain at rest or recent acute lower-limb trauma.\n* Diagnosed structural or inflammatory joint disorders.\n* Current or recent physiotherapy targeting knee pain (within 6 months).\n* Allergy to fish or any study product ingredients.\n* Scheduled lower-limb surgery during the study period.\n* Other musculoskeletal disorders affecting ambulation.\n* Recent joint injections (within 3 months).\n* Use of joint supplements in the past 3 months.\n* Use of analgesics ≥3 days\u002Fweek in the past 3 months.\n* NSAIDs\u002Facetaminophen use is permitted with restrictions:\n* Not within 24 hours of blood sampling or VAS assessments.\n* Must be documented.\n* Chronic use of medications that affect musculoskeletal symptoms (e.g., muscle relaxants, gabapentinoids) unless infrequent (≤2x\u002Fweek) and not within 24 hours of assessments.\n* Regular use of PPIs (\\>3x\u002Fweek in past month).\n* Systemic corticosteroids, immunosuppressants, or opioids within 4 weeks.\n* Unstable weight or significant recent dietary changes.\n* Significant medical conditions (e.g., cancer, hepatic\u002Frenal impairment, CVD, thyroid disease, diabetes).\n* Neurological, cognitive, or psychiatric disorders affecting participation.\n* Use of tobacco\u002Fnicotine or other substances.\n* Diagnosed sleep disorders.\n* Strict vegan diet or sedentary lifestyle.\n* Inability to swallow capsules.\n* Pregnant, breastfeeding, or planning pregnancy.\n* Women of childbearing potential not using contraception.\n* Participation in another interventional clinical trial.","ALL","20 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether a natural marine supplement called NT-II™ (Salmon Undenatured Type II Collagen) can help lower knee discomfort caused by physical activity in otherwise healthy adults. Many active people experience knee pain when performing daily movements like climbing stairs, walking long distances, or squatting, even if they do not have a medical diagnosis such as arthritis. This discomfort can limit mobility, impact exercise routines, and reduce overall quality of life. This study is being conducted to determine whether NT-II™, taken as a once-daily oral supplement, can reduce this type of activity-related knee discomfort more effectively than a commonly used joint supplement containing glucosamine and chondroitin.\n\nThe main questions the study aims to answer are:\n\nDoes NT-II™ reduce knee discomfort caused by repeated activity over a 12-week period?\n\nDoes NT-II™ improve movement and quality of life compared to glucosamine-chondroitin?\n\nResearchers will compare two different doses of NT-II™ (240 mg and 480 mg) to glucosamine (1500 mg) plus chondroitin (1300 mg), which is used as an active comparator. All three products will be taken once daily for 12 weeks.\n\nParticipants will:\n\nTake their assigned supplement daily by mouth for 12 weeks\n\nTrack knee discomfort once per week using a pain rating scale called a visual analog scale (VAS) while doing an activity that usually causes discomfort, such as climbing stairs, walking, or squatting\n\nComplete short surveys online about joint function, pain, and quality of life (including KOOS and SF-12 questionnaires)\n\nUse a mobile app to perform simple knee range of motion tests at home\n\nWear a fitness tracker to monitor daily physical activity, such as step count and stair climbing\n\nCollect two small blood samples at home using a finger-prick kit to check for changes in inflammation-related biomarkers\n\nThis study is for U.S.-based adults between the ages of 20 and 65 who are in generally good health but have had mild to moderate knee discomfort caused by physical activity for at least three months. The pain must be triggered by specific weight-bearing movements and be relieved by rest. Participants must not have osteoarthritis, rheumatoid arthritis, or other joint diseases. Individuals with recent knee injuries, major surgeries, or injections in the past six months cannot take part. Participants should not be using NSAIDs, turmeric, collagen, or other joint-related supplements during the study.\n\nAll study activities will take place remotely using a secure digital platform. There are no in-person clinic visits required. Eligible participants will receive all study materials by mail, including supplements, a wearable device, and an at-home blood sample collection kit. They will also be given access to a secure digital platform (Alethios) where they can complete questionnaires, enter pain ratings, and receive study instructions. Study staff will monitor progress, check for missing data, and assist participants through secure communication tools built into the platform.\n\nThe primary outcome of the study is the change in participant-reported knee discomfort, measured using a nominated activity VAS score (VASNA), from baseline to week 12. Additional outcomes will explore changes in function, mobility, physical activity, heart rate variability, and inflammatory biomarkers. The Pain Catastrophizing Scale (PCS) will also be used to examine whether thoughts and feelings about pain influence symptom reporting and treatment response.\n\nThis trial is sponsored by Hofseth BioCare ASA and is being conducted entirely online to improve access, lower participant burden, and support real-world understanding of joint health supplements. Study results may inform the use of NT-II™ as a marine-based nutritional strategy to support joint comfort in active individuals.",[28,29,30,31,32],"Activity-Related Knee Discomfort","Joint Discomfort","Functional Joint Pain","Functional Knee Pain","Knee Acute and Chronic Pain",[34,35,36,37,38,39,40,41,42,43,44,45],"Undenatured Type II Collagen","NT-II™","Salmon Collagen","Glucosamine","Chondroitin","Joint Health","Knee Pain","Range of Motion","Activity-Related Pain","Inflammation","Decentralized Clinical Trial","Activity-related Knee Discomfort","RECRUITING","2026-05-12",{"date":49,"type":50},"2026-05-14","ACTUAL",{"date":52,"type":50},"2025-01-20",{"date":54,"type":22},"2026-10-15",{"name":56,"class":57},"Hofseth Biocare ASA","INDUSTRY",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":23,"phases":71,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":58},"100632463","examining-olive-oil-extract-on-knee-comfort-and-function-100632463","NCT07514013","Examining Olive Oil Extract on Knee Comfort and Function","A 6-Week, Randomized, Double-Blind, Placebo-Controlled Virtual Study Evaluating an Olive Oil Extract on Knee Comfort and Function","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n* Adults aged 40 to 75 years\n* Self-reported knee discomfort for at least 3 months\n* Willing and able to take one study capsule daily for the duration of the study\n* Willing and able to complete digital questionnaires, functional movement tasks, and other study activities using the Alethios platform\n* Willing and able to wear a compatible activity-tracking device throughout the study\n* Willing and able to collect saliva samples at home using a provided kit, if applicable\n* Able to read and understand English\n* Willing to provide informed consent electronically\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\n* Diagnosis of inflammatory joint disease (e.g., rheumatoid arthritis) or other systemic inflammatory conditions affecting the knee\n* Any current or prior diagnosis from a licensed medical provider of knee disease\n* Knee surgery or significant knee injury within the past 6 months\n* Planned knee surgery during the study period\n* Known allergy or sensitivity to olive-derived products or any component of the study product\n* Current use of investigational drugs or participation in another research study during the study period\n* Any medical condition or circumstance that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data quality",true,"40 Years","75 Years",{"count":70,"type":22},168,[25],"The goal of this study is to learn if an olive oil extract works to improve knee pain and discomfort in adults. The main questions it aims to answer are: 1) Does the olive oil extract improve the perceptions of knee pain and discomfort, and 2) Does the olive oil extract improve knee function in adults?\n\nThe main procedures in the study include:\n\n* Screening and informed consent\n* Take one assigned study capsule (supplement or placebo) daily with food for 6 weeks\n* Complete digital questionnaires about your knee pain, stiffness, and function at scheduled times\n* Complete a Day 1 acute assessment and two simple functional movement tests at home as described below\n* If possible, connect a compatible wearable device to allow collection of sleep and physical activity data as detailed below.\n* Collect saliva samples at home using a provided kit at designated timepoints\n* Record any pain medications taken during the study or any side effects",[74,75,29],"Healthy Adult Male","Healthy Adult Females",[77,78,79,80,81],"olive oil extract","randomized","double-blind","placebo","joint discomfort","2026-04-10",{"date":84,"type":50},"2026-04-15",{"date":86,"type":22},"2026-04",{"date":88,"type":22},"2026-11-01",{"name":90,"class":57},"Applied Food Sciences Inc.",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":66,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":58},"100611276","jds-hf30-supplementation-on-menopause-related-quality-of-life-outcomes-in-postmenopausal-women-100611276","NCT07238478","JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women","Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of JDS-HF3.0 in Menopause Related Quality of Life Outcomes in Postmenopausal Women","Inclusion Criteria:\n\n1. Healthy biological females who are 50-70 years of age (inclusive).\n2. Have a body mass index (BMI) between 18.5 to 34.9 kg\u002Fm2 (inclusive).\n3. Self-reported as postmenopause. Defined as 12 months without a menstrual cycle in individuals who undergo \"Natural\" Menopause (Not Surgically or medically induced) and who have self-reported menopausal outcomes for the past 6 months.\n4. Have self-reported menopause related joint outcomes of moderate or severe severity according to a perceived discomfort greater or equal to 5 and less than 10 on a scale of 0-10 (participants rating their discomfort 5-9 will be included).\n5. Have self-reported \\> or equal to 4 hot flashes on average per day.\n6. In good general health (no active or uncontrolled diseases or conditions) and able to consume the study product.\n7. Agree to refrain from treatments listed in Section 6.5 in the defined timeframe.\n8. Have reliable, stable access to Wi-Fi and a smart phone\u002Fdevice.\n9. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n1. Individuals who are lactating, pregnant, or planning to become pregnant during the study.\n2. Active participation in a clinical trial.\n3. Use of any treatment for menopausal outcomes or other concomitant treatments for menopausal symptoms, joint health or at the discretion of the investigator. (Participants may be deemed ineligible at the discretion of the investigator if the medication may cause adverse interaction.)\n4. Have a known sensitivity, intolerability, or allergy to any of the study product or their excipients.\n5. Use of Glucosamine and\u002For Chondroitin for joint outcomes in the last 3 months prior to screening.\n6. Received a COVID-19 vaccine in the 2 weeks prior to screening or during the study period, current COVID-19 infections or currently have the post-COVID-19 condition as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnosis).\n7. Have a positive medical history of heart disease, renal disease, hepatic impairment, or active systemic infection (i.e., Lyme disease, TB, HIV).\n8. History of cancer (except localized skin cancer without metastases) within two (2) years prior to screening.\n9. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study or influence the results or the potential subject's ability to participate in the study.\n10. History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e., Crohn's disease, short bowel, acute or chronic pancreatitis, gastric bypass procedures, or pancreatic insufficiency).\n11. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).\n12. Major surgery in three months prior to screening or planned major surgery during the study.\n13. History of alcohol or substance abuse in the last 5 years.\n14. Has evidence of inflammatory rheumatic disease or other diagnosed anti-inflammatory disease.\n15. Has evidence of autoimmune disease(s).\n16. Chronic use of curcumin or curcuminoids in an herbal or dietary supplement. Note: Screened participants that are willing to undergo a washout period of at least 3 months prior to participation in the trial can be enrolled.\n17. Chronic pain medication and use of analgesics specifically for joint-related discomfort (i.e. Opiates, Tramadol) Note: Screened participants that are willing to undergo a washout period of at least 2 weeks during the duration of the trial can be enrolled.\n18. Have severe joint and\u002For severe bone deformities.\n19. Diagnosed bone fractures.\n20. Are a candidate for surgical joint replacement.","FEMALE","50 Years","70 Years",{"count":102,"type":22},250,[25],"The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70. The primary research question is whether taking the study product daily for 12 weeks can reduce the severity and frequency of menopause-related symptoms.",[29,106,107,108,109,110,111],"Joint Pain, Stiffness, Function","Joint Pain","Hot Flashes","Hot Flash","Night Sweats","Vasomotor Symptoms",[113,114,111,115,108,107,29,116,117],"Postmenopausal","Post menopause","Night sweats","Non-hormonal Treatment","Supplement","2025-11-18",{"date":120,"type":50},"2025-11-20",{"date":122,"type":50},"2025-05-14",{"date":124,"type":22},"2026-10",{"name":126,"class":57},"Bonafide Health"]